Objective To investigate the clinical effect and Insulin resistant influence of Rosiglitazone combined Metformin in patient with Type 2 Diabetes Mellitus ( T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD).Methods 100 patients of T2DM and NAFLD who have been treated in our department from January, 2011 to September, 2014 were randomly divided into control group 50 cases and observation group 50 cases.Under the premise of hygiene education, diet control and reasonable exercise, all patients were treatment with Rosiglitazone and Metformin.Then, we observed the changes of clinical effect, adverse reaction and clinical biochemical indices after 6 months.Results (1) In observation group, the clinical effect was 90.0%which was significantly better than those in control group (72.0%), (P <0.05).Also, there was no severe adverse reaction during treatment course.( 2 ) After treatment, the indices of insulin resistance, glucose and lipid metabolism and enzyme Levels were ameliorated in both 2 groups (P<0.05 or 0.01).In addition, the results of the observation group were much better than control group (P<0.05 or 0.01).Conclusions Treatment with Rosiglitazone and Metformin could significantly increase the clinical effect in the patients with T2DM and NAFLD. Besides, there was no severe adverse reaction during treatment course.In addition, this treatment protocol is safe and could ameliorate insulin resistance, glucose and lipid metabolism and enzyme Levels.Therefore, Treatment with Rosiglitazone and Metformin is an effective protocol and might be popularized to clinical practice.%目的：探讨罗格列酮联合二甲双胍治疗2型糖尿病（ T2MD）并非酒精性脂肪性肝病（ NAFLD）的疗效及对胰岛素抵抗的影响。方法选择我院2011年1月至2014年9月收治的100例T2MD并NAFLD患者，随机分为对照组50例和观察组50例。在卫生宣教、积极控制饮食和合理运动的前提下，观察组：罗格列酮联合二甲双胍，对照组：罗格列酮进行治疗，6月后观察临床疗效、不良反应的发生情况和生化等指标的变化。结果（1）观察组临床总疗效达90．0％，明显优于对照组（72．0％）（ P＜0．05）；在用药期间患者未出现严重的不良反应事件。（2）两组治疗后均有改善糖脂代谢、降酶和减轻胰岛素抵抗的效果（P＜0．05或0．01），但观察组的改善程度较之对照组更明显（P＜0．05或0．01）。结论罗格列酮联合二甲双胍治疗T2MD并NAFLD可显著提高临床疗效，在用药期间无严重不良事件发生，用药安全。并能显著改善糖脂代谢异常、降酶和减低胰岛素抵抗，是治疗T2MD并NAFLD的有效方案，有临床推广应用价值。
展开▼
